explore -WSS

explore

author：Wikipedia 2025-09-28 01:39:24 - browse：4

Two boxes of Ozempic stack on each other, while one lean on the stack tilted — health coverage from STAT — SEBASTIEN BOZON/AFP via Getty Images

Novo Nordisk’s Ozempic cut the risk of death in a trial of patients with type 2 diabetes and chronic kidney disease, suggesting it may offer some added benefits over other classes of drugs approved to treat this population.

Specifically, the diabetes drug cut the risk of cardiovascular-related deaths by 29% and all-cause deaths by 20%. Given the study parameters, this implies that over three years, 39 people would need to be treated to prevent one death from any cause, according to new results presented Friday at a meeting of the European Renal Association and published in the New England Journal of Medicine.

Ozempic also lowered the risk of major heart complications — including cardiovascular-related death, heart attack, or stroke — by 18%, driven primarily by the reduced rate of heart-linked death.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： HHS names first

focus

WSS

Readout LOUD podcast: ESMO highlights & Roivant's big deal

What is microchimerism and how does it affect maternal health?

Heart disease and mental health: A look at cardiac psychology

DeepMind touts AlphaFold's new skills as protein folding AI models face off

Heart disease and mental health: A look at cardiac psychology

Explaining an after

hotspot

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Medicare proceeds with plan to claw back hospital funds

Jerome Adams on the need for new antivirals for Covid

Generative AI mines health records to identify patients’ social needs

Bright Health sells Medicare Advantage business to Molina

Why liver experts renamed NASH to MASH, and NAFLD to MASLD

Supreme Court strikes down use of affirmative action

FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

Affirmative action in medical school literally saved lives

Life sciences investors close nearly $6 billion in new funds

focus

Heart disease and mental health: A look at cardiac psychology

New Medicare drug pricing powers could soon be upended in court

Risky weight loss products often used by teens globally, per study

New England Journal of Medicine addresses racist history, slavery

Readout LOUD podcast: live from JPM 2024

Lung cancer screening guidelines updated for cigarette smokers

leisure time

focus

focus

leisure time